MARKET PULSE-Enzymotec, Celldex, Summer Infant, Gramercy Property Trust

Wed May 14, 2014 11:25am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(For more market insights, including options activity, click on ; for the Day Ahead newsletter; for the Morning News Call newsletter, U.S. stocks fell on Wednesday as investors found few reasons to keep pushing shares higher, with the Dow and S&P 500 both modestly coming off their record closing highs. The Dow Jones industrial average was down 0.32 percent at 16,662.25, and the S&P 500 was down 0.21 percent at 1,893.5.

** SEARS HOLDINGS CORP, $43.48, +0.58 pct

The department store operator said it was looking to sell its 51 percent stake in Sears Canada, in a process that could result in all of the struggling Canadian department store operator being put up for sale.


The pharmaceutical company said it would acquire the U.S. marketing rights to GlaxoSmithKline's migraine drug Treximet for an upfront payment of $250 million.

Acquiring the rights to the drug, which had annual sales of $78.7 million in 2013, will nearly double Pernix's revenue, the company said.

** SUMMER INFANT INC, $2.41, +45.18 pct   Continued...